Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Coleman

Showing results (181-190 of 1,813) with videos related to

Pageof 182
Sort By:
Nature Medicine|May 9, 2009
Angiogenesis: escape from hypoxiaMathew L Coleman, Peter J Ratcliffe
Connecticut Medicine|February 1, 1980
Gentamicin: clinical roleD L Coleman, J L Ryan
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2016
Saving the best treatment for last?R L Coleman, B J Monk
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|January 1, 1995
Contemporary quality management in mental healthR L Coleman, D E Hunter
Transactions of the American Ophthalmological Society|January 1, 1990
Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleateA L Robin, A L Coleman
Future Oncology (London, England)|April 24, 2014
Vintafolide: a novel targeted agent for epithelial ovarian cancerWhitney S Graybill, Robert L Coleman
Infection and Immunity|September 23, 2003
The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune systemJames L Coleman, Jorge L Benach
Cancer Journal (Sudbury, Mass.)|December 14, 2021
The Principles and Practice of PARP Inhibitor TherapyTimothy A Yap, Robert L Coleman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancerBrian M Slomovitz, Robert L Coleman
Bulletin of Environmental Contamination and Toxicology|February 1, 1973
Cadmium toxicity and accumulation in southern naiadJ E Cearley, R L Coleman
Pageof 182

Showing results (181-190 of 1,813) with videos related to

Sort By:
Pageof 182
Nature Medicine|May 9, 2009
Angiogenesis: escape from hypoxiaMathew L Coleman, Peter J Ratcliffe
Connecticut Medicine|February 1, 1980
Gentamicin: clinical roleD L Coleman, J L Ryan
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2016
Saving the best treatment for last?R L Coleman, B J Monk
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|January 1, 1995
Contemporary quality management in mental healthR L Coleman, D E Hunter
Transactions of the American Ophthalmological Society|January 1, 1990
Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleateA L Robin, A L Coleman
Future Oncology (London, England)|April 24, 2014
Vintafolide: a novel targeted agent for epithelial ovarian cancerWhitney S Graybill, Robert L Coleman
Infection and Immunity|September 23, 2003
The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune systemJames L Coleman, Jorge L Benach
Cancer Journal (Sudbury, Mass.)|December 14, 2021
The Principles and Practice of PARP Inhibitor TherapyTimothy A Yap, Robert L Coleman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancerBrian M Slomovitz, Robert L Coleman
Bulletin of Environmental Contamination and Toxicology|February 1, 1973
Cadmium toxicity and accumulation in southern naiadJ E Cearley, R L Coleman
Pageof 182